Richard Glover, MD
Family Medicine · Newton, KSNPI 1063480937
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.4% of the total across 890 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 50 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 890 payments — averaging $15.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Pfizer$2K
- Lilly USA, LLC$1K
- Novo Nordisk$904
- Eli Lilly$888
- Amgen$837
- plus $5K from 44 others
Across 3,283 payments — averaging $5992.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$11M
- Pfizer$3.8M
- Sanofi Pasteur Inc.$886K
- Emergent Biosolutions Inc.$835K
- Eli Lilly$593K
- Valneva Austria GmbH$580K
- plus $2M from 12 others
What the payments were for
- Travel & lodging$1,2729%
- Food & beverage$12,74090%
- Education$590%
- Gifts$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,091 in reported general payments places this provider in the 95th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 90 | $86,222 |
| FarxigaDapagliflozin Propanediol | 80 | $66,510 |
| JardianceEmpagliflozin | 47 | $58,991 |
| EliquisApixaban | 61 | $54,617 |
| Tresiba Flextouch U-200Insulin Degludec | 39 | $37,919 |
| MounjaroTirzepatide | 26 | $29,832 |
| XareltoRivaroxaban | 49 | $26,474 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 24 | $22,184 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $17,529 |
| MyrbetriqMirabegron | 16 | $9,931 |
| LinzessLinaclotide | 11 | $6,296 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 160 | $4,268 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 11 | $3,428 |
| Arnuity ElliptaFluticasone Furoate | 13 | $3,415 |
| PaxlovidNirmatrelvir/Ritonavir | 11 | $2,858 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $904 | $86,22290 claims |
| AstraZenecaFarxiga, Symbicort | $715 | $69,02191 claims |
| PfizerEliquis, Abrysvo, Paxlovid | $2,450 | $60,90383 claims |
| Boehringer IngelheimJardiance | $72 | $58,99147 claims |
| Lilly USA, LLCMounjaro | $1,392 | $29,83226 claims |
| Johnson & JohnsonXarelto | $99 | $26,47449 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $12 | $22,18424 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $107 | $20,94430 claims |
| Astellas Pharma US IncMyrbetriq | $407 | $9,93116 claims |
| AbbVieLinzess | $2,527 | $6,29611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Newton
- Bradley HarrisonManhattan$314K
- Mila MeansWichita$241K
- Scott AveryJunction City$195K
- Kent KiracofeManhattan$189K
- Terry McGeeneyLeawood$147K
- Cole GillenwaterWichita$62K
- David StricklandLawrence$53K
- Kyle PlatzManhattan$51K
- Eric AspinwallKansas City$28K
- Hai TruongWichita$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.